Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Daily volatility informs risk tolerance and timing decisions. This overview highlights why investors should monitor volatility and adjust strategies.
28,131 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
When Netflix reportedly missed out on Roku, investors asked: what does this mean for the company’s future profits and...
SpaceX stunned markets with a massive IPO haul and a rapid follow-up bond issue. This article breaks down what happen...
Netflix faces a crossroads: expand by merging with major studios or double down on core strengths. This piece argues ...
G-III Apparel faced a sharp slide after its latest earnings, signaling investor caution about licensing-heavy fashion...
Investors are weighing CoreWeave against top AI stocks. This guide explains the risks, introduces three solid alterna...
After a string of near-misses, Netflix finally makes acquisition that seems to align with its long-term plan. This pi...
TTRF Capital Ltd quietly added a new stake in IREN Limited, buying 66,800 shares worth about $3.1 million. This shift...
A sharp rally in Chime Financial shares followed stronger-than-expected Q4 guidance. This piece breaks down the drive...
Dive into gigacloud (gct) 2025 earnings with a clear, actionable analysis. We break down the Q4 results, growth drive...
Lucid has set a production target, but many investors wonder if the pace will match the plan. This deep dive explains...
Jim Cramer warns that AppLovin's blistering margins could attract a Google-sized challenger in ad tech. The alert fol...